Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

How Much is Too Much to Pay for Newly Approved Drugs?

For patients with deadly and debilitating conditions, FDA drug approvals can be cause for celebration. Many of these patients and their families have been waiting years for better therapies – or any therapy at all. They consume every public announcement about drug approvals for their particular disease like it’s water in the desert. But there is also a sense of trepidation once the drug launches. How much will this new drug cost? What will insurance cover? What will be our share?

Read More »

FDA Approves BioMarin’s drug for Batten Disease

BioMarin Pharmaceutical announced that the U.S. FDA approved Brineura (cerliponase alfa) for the rare disease, late infantile neuronal ceroid lipofuscinosis type 2 (CLN2).

Read More »

Horizon Pharma Buys Raptor in $800 Million Deal

Shares of Raptor Pharmaceutical Corp. were up after Horizon Pharma announced it had struck a deal to acquire the rare disease company for $800 million.

Read More »

Protalix Sells Back ELELYSO Rights to Pfizer for $46 Million

Karmiel, Israel-based Protalix Biotherapeutics, Inc. (PLX) announced today that it was selling its share of a collaboration deal back to Pfizer Inc. (PFE)   Under the original deal, Pfizer took 60 percent and Protalix took 40 percent of revenues and expenses for the development and commercialization of ELELYSO, except in Israel and Brazil. Under the […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom